Myriad Genetics (MYGN) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY25 Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.05, $0.06 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $213.1 million versus the consensus estimate of $201.91 million.

GUIDANCE:

Myriad Genetics sees FY2025 EPS of ($0.02)-$0.02, versus the consensus of ($0.01). Myriad Genetics sees FY2025 revenue of $818-828 million, versus the consensus of $811 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Trump on Iran: we're trying to work out a deal that's fair
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance